

# Give your EGFRm+ NSCLC patients the opportunity to extend their time on oral targeted therapies<sup>1\*</sup>



## GioTag<sup>1</sup>

Del19

149

mTOT

**30.0**  
months

(90% CI: 27.6 -31.9)

## GioTag<sup>1</sup>

Asian + Del19

31

mToT

**40.0**  
months

(90% CI: 36.4-45.0)

## RESET<sup>2</sup>

Korean + Del19

77

mToT

**40.9**  
months

(95% CI: 27.8-49.5)

mOS

**41.6**  
months

(90% CI: (36.9-45.0))

mOS

**45.7**  
months

(90% CI: 38.2-57.8)

mOS

**NR**

(95% CI: NA-NA)

- **GioTag** is a retrospective, observational, multicenter, global study evaluating efficacy and safety of the first-line GIOTRIF<sup>®</sup> followed by osimertinib in case patients eveloped T790M mutation at the time of progression on GIOTRIF<sup>®</sup>.
- **RESET** is a retrospective, observational, multicenteer study across 16 medical centers in South Korea evaluating in clinicl characteristic and treatment outcomes in patients with EGFRm+ NSCLC who received 1st-line treatment with GIOTRIF<sup>®</sup> and second line therapy with either osimertinib or other regimens.

NSCLC=non-small cell lung cancer; EGFRm+=epidermal growth factor receptor mutation positive; Del19=Deletion 19; mTOT=median time on treatment;

mOS=median overall survival, CI=confidence interval; NR=not reached; NA=not available

References 1. Hochmair M, et al. Future Oncol 2020;16(34):2799-2808. 2. Kim T, et al. Cancer Med 2021;10:5809-5822.

\*Patients who acquire a T790M mutation on progression with GIOTRIF<sup>®</sup> in 1st-line.

